Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Gross

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
Case Reports in Endocrinology|April 21, 2018
Adrenocorticotropic Hormone Secreting Pheochromocytoma Underlying Glucocorticoid Induced Pheochromocytoma CrisisGil A Geva, David J Gross, Haggi Mazeh, et al.
Journal of the Endocrine Society|August 11, 2022
Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center's 20 years of ExperienceJohnathan Arnon, Simona Grozinsky-Glasberg, Kira Oleinikov, et al.
Cancer|July 14, 2011
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors: clinical experience with a rare entityAlexander Gorshtein, David J Gross, Dganit Barak, et al.
EJNMMI Physics|June 20, 2018
Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)Alexandre Chicheportiche, Faozi Artoul, Arnon Schwartz, et al.
EJNMMI Physics|January 25, 2020
Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient managementAlexandre Chicheportiche, Simona Ben-Haim, Simona Grozinsky-Glasberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivoDavid J Gross, Israel Reibstein, Lola Weiss, et al.
EJNMMI Physics|December 12, 2018
Predictive power of the post-treatment scans after the initial or first two courses of [<sup>177</sup>Lu]-DOTA-TATEAlexandre Chicheportiche, Simona Grozinsky-Glasberg, David J Gross, et al.
European Journal of Endocrinology|May 4, 2019
Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center studyOrit Twito, Simona Grozinsky-Glasberg, Sigal Levy, et al.
Archives of Pathology & Laboratory Medicine|November 7, 2018
The Role of the Pathologist in Population HealthDavid J Gross, Mary Kennedy, Tarush Kothari, et al.
European Journal of Endocrinology|November 8, 2012
Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter studyDimitrios Thomas, Apostolos V Tsolakis, Simona Grozinsky-Glasberg, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Case Reports in Endocrinology|April 21, 2018
Adrenocorticotropic Hormone Secreting Pheochromocytoma Underlying Glucocorticoid Induced Pheochromocytoma CrisisGil A Geva, David J Gross, Haggi Mazeh, et al.
Journal of the Endocrine Society|August 11, 2022
Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center's 20 years of ExperienceJohnathan Arnon, Simona Grozinsky-Glasberg, Kira Oleinikov, et al.
Cancer|July 14, 2011
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors: clinical experience with a rare entityAlexander Gorshtein, David J Gross, Dganit Barak, et al.
EJNMMI Physics|June 20, 2018
Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)Alexandre Chicheportiche, Faozi Artoul, Arnon Schwartz, et al.
EJNMMI Physics|January 25, 2020
Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient managementAlexandre Chicheportiche, Simona Ben-Haim, Simona Grozinsky-Glasberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivoDavid J Gross, Israel Reibstein, Lola Weiss, et al.
EJNMMI Physics|December 12, 2018
Predictive power of the post-treatment scans after the initial or first two courses of [<sup>177</sup>Lu]-DOTA-TATEAlexandre Chicheportiche, Simona Grozinsky-Glasberg, David J Gross, et al.
European Journal of Endocrinology|May 4, 2019
Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center studyOrit Twito, Simona Grozinsky-Glasberg, Sigal Levy, et al.
Archives of Pathology & Laboratory Medicine|November 7, 2018
The Role of the Pathologist in Population HealthDavid J Gross, Mary Kennedy, Tarush Kothari, et al.
European Journal of Endocrinology|November 8, 2012
Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter studyDimitrios Thomas, Apostolos V Tsolakis, Simona Grozinsky-Glasberg, et al.
Pageof 8